Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $15.00.